Formulations in early clinical development require a delicate balance of flexibility, simplicity, and scientific rigor. In first‑in‑human trials, dose ranges can vary by 10–100 fold increase between the starting dose a...
Filter media
Filter media articles by either clicking within the ‘Category’ drop-down list, or begin typing which will automatically match to the nearest available category. Note - not all categories will display results if selecting a particular year.
-
-
The Irish Times Business Person of the Month: Steve Cutler
ICON CEO Steve Cutler has been chosen as The Irish Times Business Person of the Month for February 2021.
-
US Regulators question AstraZeneca vaccine trial data
ICON's Dr. Andrew Garrett, Executive Vice President of Scientific Operations, weighs in on potential safety issues with the AstraZeneca COVID-19 vaccine.
-
What does it really take to conduct a vaccine trial at scale?
Dr Nuala Murphy, President of Clinical Services, talks exclusively to Pharmafield about the Pfizer / BioNTech COVID-19 vaccine trial and the implications this has on the future of drug development.
-
International Women's Day: An interview with Cindy Spittle
In this interview, Cindy Spittle talks about the women role models who provided inspiration in her career in honour of International Women's Day.
-
International Women's Day: An interview with Marelise Epstein
Marelise Epstein is interviewed for International Women's Day and provides a glimpse into her work day and what inspires her.
-
Steve Cutler: ‘People understand what a clinical trial is now’
An interview with CEO Steve Cutler on ICON's recent acquisition of PRA Health Sciences.
-
Mind the gap: Managed access programmes as an alternative to long-term follow up studies
Veronica Gutierrez Martinez and Michael Tokar discuss the challenges of setting up MAPs and the various considerations that must be tackled for a successful programme.
-
Ensuring patient safety and cardiovascular clinical trial integrity during a global pandemic
Jack Martin and Deirdre Albertson provide insights on ensuring patient safety and cardiovascular clinical trial integrity during a global pandemic.
-
Minimising the risk of mistakes in HTA
An article in Pharmexec examining mistakes made in relation to Health Technology Assessments (HTA) and strategies to help reduce risks of future mistakes. ICON’s (ICER’s impact on payer decision making) whitepaper was referenced in the article.
